X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (20136) 20136
Newsletter (148) 148
Patent (131) 131
Book Chapter (101) 101
Book / eBook (25) 25
Dissertation (22) 22
Magazine Article (18) 18
Conference Proceeding (7) 7
Web Resource (7) 7
Publication (6) 6
Newspaper Article (5) 5
Book Review (4) 4
Reference (2) 2
Streaming Video (2) 2
Transcript (2) 2
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (9071) 9071
animals (8170) 8170
nucleosides (4844) 4844
pharmacology & pharmacy (4626) 4626
biochemistry & molecular biology (3185) 3185
nucleosides - pharmacology (3018) 3018
mice (2690) 2690
chemistry, medicinal (2682) 2682
male (2680) 2680
female (2212) 2212
rats (2187) 2187
antiviral agents - pharmacology (2172) 2172
kinetics (1990) 1990
structure-activity relationship (1836) 1836
cell line (1794) 1794
nucleoside analogs (1588) 1588
nucleotides (1512) 1512
antiviral agents (1344) 1344
nucleosides - metabolism (1292) 1292
molecular structure (1183) 1183
nucleosides - chemistry (1176) 1176
nucleoside (1163) 1163
cells, cultured (1145) 1145
hiv-1 - drug effects (1124) 1124
research (1124) 1124
cell line, tumor (1116) 1116
dna (1108) 1108
antineoplastic agents - pharmacology (1101) 1101
oncology (1079) 1079
adenosine (1075) 1075
in vitro techniques (1045) 1045
dose-response relationship, drug (1044) 1044
virology (1041) 1041
mutation (1040) 1040
hiv (1029) 1029
antiviral agents - chemical synthesis (1019) 1019
microbiology (1007) 1007
anti-hiv agents - pharmacology (985) 985
analysis (984) 984
analogs (957) 957
chemistry, organic (952) 952
antiviral agents - chemistry (922) 922
pharmacology (915) 915
enzyme inhibitors - pharmacology (899) 899
cancer (898) 898
derivatives (896) 896
cells (885) 885
adult (872) 872
antiviral activity (871) 871
metabolism (867) 867
hiv infections - drug therapy (851) 851
nucleosides - chemical synthesis (845) 845
enzymes (835) 835
in-vitro (829) 829
inhibition (823) 823
reverse transcriptase inhibitors - pharmacology (821) 821
pyrimidines (816) 816
time factors (804) 804
phosphorylation (803) 803
chemistry (802) 802
models, molecular (795) 795
virus replication - drug effects (791) 791
infectious diseases (781) 781
drug resistance (776) 776
expression (770) 770
proteins (758) 758
tritium (752) 752
chemistry, multidisciplinary (730) 730
heterocyclic compounds (716) 716
inhibitors (715) 715
drug design (707) 707
middle aged (707) 707
tumor cells, cultured (699) 699
cell biology (684) 684
cell survival - drug effects (684) 684
research article (684) 684
adenosine - pharmacology (682) 682
thymidine (680) 680
drugs (675) 675
replication (657) 657
nucleotides - pharmacology (638) 638
microbial sensitivity tests (637) 637
rna (636) 636
resistance (632) 632
therapy (632) 632
viruses (603) 603
molecular sequence data (599) 599
magnetic resonance spectroscopy (598) 598
human-immunodeficiency-virus (596) 596
binding sites (593) 593
adenosine - metabolism (581) 581
organic compounds (574) 574
cell division - drug effects (568) 568
adenine - analogs & derivatives (553) 553
thymidine - metabolism (553) 553
adenine - pharmacology (549) 549
health aspects (544) 544
substrate specificity (544) 544
toxicology (544) 544
pyrimidine nucleosides - pharmacology (540) 540
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (19999) 19999
Japanese (461) 461
German (221) 221
Russian (129) 129
Chinese (107) 107
French (107) 107
Italian (59) 59
Spanish (18) 18
Ukrainian (12) 12
Czech (9) 9
Polish (9) 9
Portuguese (5) 5
Slovak (5) 5
Dutch (3) 3
Hungarian (3) 3
Turkish (2) 2
Bulgarian (1) 1
Croatian (1) 1
Korean (1) 1
Norwegian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


American Journal of Physiology - Endocrinology and Metabolism, ISSN 0193-1849, 11/2016, Volume 311, Issue 5, pp. E859 - E868
Journal Article
Mayo Clinic Proceedings, ISSN 0025-6196, 2011, Volume 86, Issue 10, pp. 1009 - 1026
Abstract Most viral diseases, with the exception of those caused by human immunodeficiency virus, are self-limited illnesses that do not require specific... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | HERPES-SIMPLEX-VIRUS | TENOFOVIR DISOPROXIL FUMARATE | PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY | POSITIVE CHRONIC HEPATITIS | CHRONIC HEPATITIS-B | ALPHA-2A PLUS RIBAVIRIN | CONGO HEMORRHAGIC-FEVER | ACUTE INTERSTITIAL NEPHRITIS | RECURRENT GENITAL HERPES | HIV-INFECTED PATIENTS | Acyclovir - therapeutic use | Foscarnet - pharmacology | Hepatitis C - drug therapy | HIV Infections - epidemiology | Humans | Ganciclovir - analogs & derivatives | Interferons - therapeutic use | Oligopeptides - therapeutic use | Hepatitis - drug therapy | Valacyclovir | Adenine - therapeutic use | Lamivudine - therapeutic use | Ganciclovir - therapeutic use | Proline - pharmacology | Protease Inhibitors - therapeutic use | Guanine - therapeutic use | Oseltamivir - pharmacology | Virus Replication - drug effects | Antiviral Agents - pharmacology | Adenine - analogs & derivatives | Valganciclovir | Organophosphonates - therapeutic use | Proline - analogs & derivatives | Antiviral Agents - therapeutic use | Comorbidity | Interferons - pharmacology | Pyrimidinones - therapeutic use | Acyclovir - pharmacology | Zanamivir - therapeutic use | Herpesviridae Infections - drug therapy | Thymidine - analogs & derivatives | Valine - therapeutic use | Oligopeptides - pharmacology | Telbivudine | Ribavirin - pharmacology | Guanine - analogs & derivatives | Oseltamivir - therapeutic use | Guanine - pharmacology | Hepatitis C - epidemiology | Nucleosides - pharmacology | Ganciclovir - pharmacology | Pyrimidinones - pharmacology | Influenza, Human - drug therapy | Drug Therapy, Combination | Nucleosides - therapeutic use | Acyclovir - analogs & derivatives | Ribavirin - therapeutic use | Valine - analogs & derivatives | Zanamivir - pharmacology | Adenine - pharmacology | Proline - therapeutic use | Organophosphonates - pharmacology | Hepatitis B, Chronic - drug therapy | HIV Infections - drug therapy | Lamivudine - pharmacology | Foscarnet - therapeutic use | Valine - pharmacology | Amantadine - pharmacology | Antiviral agents | Diagnosis | Research | Drug therapy | HIV infection | Health aspects | Symposium on Antimicrobial Therapy
Journal Article
Cell reports (Cambridge), ISSN 2211-1247, 2016, Volume 16, Issue 10, pp. 2576 - 2592
The mechanisms underlying Zika virus (ZIKV)-related microcephaly and other neurodevelopment defects remain poorly understood. Here, we describe the derivation... 
NEURAL PROGENITORS | LONG-TERM | HUMAN BRAIN | ADAPTER | CENTRAL-NERVOUS-SYSTEM | INFECTION | MICE | BINDING KINASE 1 | ORGANOIDS | INNATE IMMUNITY | CELL BIOLOGY | Neocortex - pathology | Neurons - pathology | Transcription, Genetic - drug effects | Brain - embryology | Neuroglia - ultrastructure | Neuroglia - pathology | Humans | Brain - virology | Centrosome - drug effects | Gene Expression Profiling | Microcephaly - virology | Neural Stem Cells - ultrastructure | Zika Virus Infection - virology | Neural Stem Cells - immunology | Neuroepithelial Cells - immunology | Neuroprotective Agents - pharmacology | Spinal Cord - pathology | Microcephaly - pathology | Neuroepithelial Cells - virology | Nucleosides - pharmacology | Fetus - virology | Cell Death - drug effects | Phosphorylation - drug effects | Neurons - drug effects | Protein-Serine-Threonine Kinases - metabolism | Zika Virus - pathogenicity | Proto-Oncogene Proteins - metabolism | Zika Virus - ultrastructure | Neurons - virology | Virus Replication - drug effects | Neuroepithelial Cells - ultrastructure | Immunity, Innate - drug effects | Zika Virus Infection - pathology | Neural Stem Cells - virology | Zika Virus - physiology | Zika Virus - drug effects | Mitochondria - metabolism | Mitochondria - drug effects | Receptor Protein-Tyrosine Kinases - metabolism | Neural Stem Cells - enzymology | Centrosome - metabolism | Mitosis - drug effects | Brain - pathology | Protein Kinase Inhibitors - pharmacology | Neuroglia - virology | Neuroepithelial Cells - drug effects | Neurons/pathology | Zika Virus/pathogenicity | Mitochondria/metabolism | Virus Replication/drug effects | Microcephaly/pathology | Neurons/drug effects | Protein-Serine-Threonine Kinases/metabolism | Neural Stem Cells/immunology | Neuroglia/ultrastructure | Neuroepithelial Cells/drug effects | Neuroepithelial Cells/virology | Life Sciences | Brain/pathology | Zika Virus/drug effects | Brain/embryology | Mitochondria/drug effects | Fetus/virology | Neocortex/pathology | Neuroglia/pathology | Cell Death/drug effects | Mitosis/drug effects | Transcription, Genetic/drug effects | Nucleosides/pharmacology | Neural Stem Cells/enzymology | Neural Stem Cells/ultrastructure | Neuroepithelial Cells/ultrastructure | Receptor Protein-Tyrosine Kinases/metabolism | Microcephaly/virology | Proto-Oncogene Proteins/metabolism | Neuroprotective Agents/pharmacology | Zika Virus/ultrastructure | Neuroepithelial Cells/immunology | Brain/virology | Immunity, Innate/drug effects | Spinal Cord/pathology | Zika Virus/physiology | Neuroglia/virology | Microbiology and Parasitology | Zika Virus Infection/pathology | Neurons/virology | Zika Virus Infection/virology | Neural Stem Cells/virology | Centrosome/drug effects | Protein Kinase Inhibitors/pharmacology | Centrosome/metabolism | Phosphorylation/drug effects
Journal Article
Journal Article
Antimicrobial agents and chemotherapy, ISSN 1098-6596, 2016, Volume 60, Issue 4, pp. 2281 - 2291
Deciphering the mode of action (MOA) of new antibiotics discovered through phenotypic screening is of increasing importance. Metabolomics offers a potentially... 
TARGET | NATURAL-PRODUCT | THYMIDYLATE KINASE | BIOSYNTHESIS | ESCHERICHIA-COLI | ALANINE LIGASE | D-CYCLOSERINE | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | STAPHYLOCOCCUS-AUREUS | MASS-SPECTROMETRY | PATHOGENS | Acyltransferases - antagonists & inhibitors | Metabolomics | Nucleoside-Phosphate Kinase - genetics | Ceftazidime - pharmacology | Escherichia coli - drug effects | Humans | Triclosan - metabolism | Triclosan - pharmacology | Acyltransferases - metabolism | Threonine - metabolism | Acyltransferases - genetics | Fosfomycin - metabolism | Pyrimidines - metabolism | DNA, Bacterial - antagonists & inhibitors | Ceftazidime - metabolism | Cell Wall - drug effects | Terpenes - antagonists & inhibitors | Terpenes - metabolism | Carbonyl Cyanide m-Chlorophenyl Hydrazone - pharmacology | Mass Spectrometry | Escherichia coli - metabolism | HEK293 Cells | Chromatography, Liquid | Hydroxamic Acids - pharmacology | Fosfomycin - analogs & derivatives | Carbonyl Cyanide m-Chlorophenyl Hydrazone - metabolism | Gene Expression | DNA, Bacterial - biosynthesis | Fosfomycin - pharmacology | Nucleoside-Phosphate Kinase - antagonists & inhibitors | Anti-Bacterial Agents - metabolism | Adenosine - pharmacology | Cell Wall - chemistry | Pyrimidines - pharmacology | Threonine - analogs & derivatives | Hydroxamic Acids - metabolism | Threonine - pharmacology | Metabolome - drug effects | Escherichia coli - genetics | Cell Wall - metabolism | Adenosine - metabolism | Anti-Bacterial Agents - pharmacology | Nucleoside-Phosphate Kinase - metabolism
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2011, Volume 11, Issue 10, pp. 769 - 779
Summary HIV-positive children are at high risk of drug resistance, which is of particular concern in settings where antiretroviral options are limited. In this... 
Infectious Disease | INFECTIOUS DISEASES | UNITED-KINGDOM | AFRICAN CHILDREN | HIV-1 DRUG-RESISTANCE | VIROLOGICAL FAILURE | INHIBITOR RESISTANCE | IMMUNODEFICIENCY-VIRUS TYPE-1 | HIV-1-INFECTED CHILDREN | PROTEASE INHIBITORS | THERAPY REGIMEN | DISEASE PROGRESSION | Anti-HIV Agents - pharmacology | Humans | Child, Preschool | Indinavir - pharmacology | Reverse Transcriptase Inhibitors - pharmacology | Male | Latin America | HIV-1 - isolation & purification | Stavudine - pharmacology | Treatment Failure | Anti-HIV Agents - therapeutic use | Female | Pyrimidinones - pharmacology | Ritonavir - pharmacology | Reverse Transcriptase Inhibitors - therapeutic use | Child | Health Resources | Cross-Sectional Studies | HIV-1 - drug effects | HIV Infections - virology | Lopinavir | Africa | Zidovudine - pharmacology | HIV-1 - genetics | Nevirapine - pharmacology | Drug Resistance, Viral - genetics | Asia | Adolescent | Benzoxazines - pharmacology | HIV Infections - drug therapy | Developing Countries | Lamivudine - pharmacology | Mutation | Viral Load - drug effects | Formulations | Antiretroviral drugs | RNA-directed DNA polymerase | Health risks | Viruses | On-line systems | Proteinase inhibitors | Drug resistance | Developing countries--LDCs | Non-nucleoside reverse transcriptase inhibitors | Salvage | Protease inhibitors | Acquired immune deficiency syndrome--AIDS | Antiretroviral agents | Nucleoside reverse transcriptase inhibitors | Human immunodeficiency virus--HIV | Nucleosides | Children
Journal Article